Merck & Co., Inc. has tweaked for the second time the lineup of antibody-drug conjugates (ADCs) it in-licensed from Chinese partner Kelun-Biotech in 2022, removing a Claudin 18.2-targeting ADC but exercising an option to add a adding a bispecific.
Claudin 18.2 has emerged as a major area of focus of R&D at innovative Chinese firms, which now have multiple assets against this target in development. (Also see "Chinese Biotechs Ascend Deal-Making By Partnering Up Claudin 18.2 Agents" - Scrip, 2 March, 2023
Key Takeaways
-
Merck & Co. has dropped SKB315(MK-1200), a Claudin 18.2-targeting ADC it in-licensed from Kelun-Biotech in 2022.
-
But the US pharma has exercised an exclusive option for non-greater China rights to SKB571, a preclinical bispecific ADC
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?